Insight journal - Company

Vertex: Partnering activity 2009-2014

Posted on 24 February 2014

Tags: , , ,

Vertex Pharmaceuticals, a biotechnology company founded in 1989 and headquartered in Massachusetts has rapidly risen as one of the leading biotechnology companies in the world.

The goal of the company is to develop new medicines that improve the lives of people with serious diseases. Currently, its therapy focus areas are genetic disorders like cystic fibrosis and immunology diseases - Hepatitis C, Influenza, etc.

Vertex constantly seeks partners developing cutting-edge medicines to aid its R&D capabilities. Vertex announced over 10 partnering / licensing deals since 2009. The partnering trends suggest that the deals where early phase deals focussed on the R&D of small molecules in the company’s main therapy focus.

Abstracted from: Partnering Agreements with Vertex Pharmaceuticals 2009-2014

The following figure shows the level of Vertex partnering deal announcements since 2009.

Figure 1: Vertex partnering deals 2009-2014

Figure 1: Vertex partnering deals 2009-2014

Figure 1: Vertex partnering deals 2009-2014

Source: Current Agreements, 2014

Analysis of the partnering deals shows a strong emphasis on partnerships in the infectives area with the deals focussed on Hepatitis C.

The following table provides an overview of the partnering deals announced by Vertex based on therapy area disclosed. Our report provides more detailed insight into the precise therapeutic target of each deal. See: Partnering Agreements with Vertex Pharmaceuticals 2009-2014                                                                          

Figure 2: Vertex partnering deals by therapy area 2009-2014

 

Figure 2: Vertex partnering deals by therapy area 2009-2014

Figure 2: Vertex partnering deals by therapy area 2009-2014

Source: Current Agreements, 2014

Further analysis of these deals shows that Vertex has a preference for collaborative R&D, development and licensing deals, similar to many other top pharmaceutical or big pharma companies. Such partnering deals provide the right for Vertex to exploit the licensors technology in return for payment of upfront, development and sales, and royalty payments.

The following table provides an overview of the partnering deals announced by Vertex based on deal type disclosed.

Figure 3: Vertex partnering deals by deal type 2009-2014

Figure 3: Vertex partnering deals by deal type 2009-2014

Figure 3: Vertex partnering deals by deal type 2009-2014

Source: Current Agreements, 2014

When looking at stage of development at partnering deal signing, the popular stages are early stage and clinical stage deal announcements. Such deals are of on-going importance to all top biopharmaceuticals companies as they seek to bolster their pipeline, fill gaps left as a result of drug candidates failing during clinical development, and ensure they have replacement products for when key drugs come off patent.

The following table provides an overview of the partnering deals announced by Vertex based on stage of development at signature.

Figure 4: Vertex partnering by stage of development 2009-2014

Figure 4: Vertex partnering by stage of development 2009-2014

Figure 4: Vertex partnering by stage of development 2009-2014

Vertex has signed over 10 partnering, collaborative R&D and licensing deals since 2009. The following provides a summary of the top deals by headline value.

Figure 5: Top Vertex partnering deals by headline value 2009-2014

 Figure 5: Top Vertex partnering deals by headline value 2009-2014

Figure 5: Top Vertex partnering deals by headline value 2009-2014

Source: Current Agreements, 2014

Our report provides more detailed insight into the details of each deal. See:  Partnering Agreements with Vertex Pharmaceuticals 2009-2014

Vertex partnering at Current Agreements

View all partnering deals for Vertex: 2014 | 2013 | 2012 | 2011 | 2010 | 2009

Full details on each deal can be found at CurrentAgreements (subscription required)

Or purchase report: Partnering Agreements with Vertex Pharmaceuticals 2009-2014

More

Summary profile data for Vertex Pharmaceuticals

Partnering interests for Vertex Pharmaceuticals 

M&A activity for Vertex Pharmaceuticals

 

Available reports from Current Partnering

Report: Partnering Agreements with Vertex Pharmaceuticals 2009-2014 

Report: Partnering Deals and Alliances with Big Biotech

 

Available resources for deal coverage for Vertex           

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Read: more on Vertex company profile, recent partnering, M&A and financing news and articles

 

Related

Report: Practical Guide to Finding Partners

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply